{'fraction_non_alphanumeric': 0.02744097000638162, 'fraction_numerical': 0.014677728142948309, 'mean_word_length': 4.872659176029963, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Virus Type 1 in Randomized Healthy Donors Immune Responses to Adeno-Associated Humoral and Cellular Capsid-Specific

A major impediment to the use of adeno-associated virus (AAV)-mediated gene delivery to muscle in clinical applications is the pre-existing immune responses against the vector. Pre-existing humoral response to different AAV serotypes is now well documented. In contrast, cellular responses to AAV capsid have not been analyzed in a systematic manner, despite the risk of T cell reactivation upon gene transfer. AAV1 has been widely used in humans to target muscle. In this study, we analyzed PBMCs and sera of healthy donors for the presence of AAV1 capsid-speciﬁc T cell responses and AAV1 neutralizing factors. Approximately 30% of donors presented AAV1 capsid-speciﬁc T cells, mainly effector memory CD8 + cells. IFN- g –producing cells were also observed among effector memory CD4 + cells for two of these donors. Moreover, to our knowledge, this study shows for the ﬁrst time on a large cohort that there was no correlation between AAV1-speciﬁc T cell and humoral responses. Indeed, most donors presenting speciﬁc Ig and neutralizing factors were negative for cellular response (and vice versa). These new data raise the question of prescreening patients not only for the humoral response, but also for the cellular response. Clearly, a better understanding of the natural immunology of AAV serotypes will allow us to improve AAV gene therapy and make it an efﬁcient treatment for genetic disease. The Journal of Immunology , 2012, 188: 000–000.